Education
About Us
Working with TipRanks
Follow Us
PolyPeptide Group AG (CH:PPGN)
:PPGN
PPGN Stock Chart & Stats
CHF24.75
CHF1.30(6.77%)
At close: 4:00 PM EST
CHF24.75
CHF1.30(6.77%)
Day’s Range― - ―
52-Week RangeCHF13.22 - CHF32.70
Previous CloseN/A
Volume22.87K
Average Volume (3M)34.07K
Market Cap
CHF815.87M
Enterprise ValueCHF917.80M
Total Cash (Recent Filing)CHF76.69M
Total Debt (Recent Filing)CHF100.45M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 12, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.78
Price to Sales (P/S)2.94
P/FCF Ratio409.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF35.50Price Target Upside43.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Comprehensive Peptide Manufacturing PlatformPolyPeptide's integrated global manufacturing and broad service offering (custom synthesis, process development, formulation) creates durable revenue stickiness and high switching costs with pharma clients. Scale and technical breadth support long-term contract wins and steady backlog growth.
Low Leverage With Strong Equity BaseA conservative capital structure with low debt provides financial flexibility to fund capacity expansion, regulatory compliance, or R&D without immediate refinancing risk. This resilience supports multi-year investments needed in peptide manufacturing and regulatory approvals.
Free Cash Flow Turned PositiveTransition to positive free cash flow signals improving operational efficiency and capital allocation. Sustained cash generation reduces dependence on external financing, enabling reinvestment in capacity and innovation, and strengthening the balance sheet over the medium term.
Bears Say
Persistent Operating LossesContinued negative operating margins show core operations are not yet profitable, which can limit retained earnings and constrain reinvestment. If margins do not convert to sustained profitability, the company may need external capital or cost restructuring, affecting long-term growth plans.
Negative Return On EquityA negative ROE indicates shareholder capital is not generating returns and reflects ongoing losses. Over time, persistent negative ROE can erode investor confidence, increase cost of capital, and limit ability to raise funds for strategic investments or capacity expansion.
Concentration In Contract Manufacturing RevenueHeavy reliance on contract manufacturing ties performance to pharmaceutical clients' R&D and procurement cycles and subjects margins to pricing pressure and client concentration. Structural exposure to biotech funding and lead-time variability can cause durable revenue and margin volatility.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF13.22 and its highest was CHF32.70 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF815.87M.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Mar 12, 2026 which is in 15 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Aug 12, 2025. The company reported -CHF0.729 earnings per share for the quarter, missing the consensus estimate of -CHF0.519 by -CHF0.21.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.26.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of -CHF0.729 in its last earnings report, missing expectations of -CHF0.519. Following the earnings report the stock price went up 9.255%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF35.50
▲(43.43% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―
Options Prices
Currently, No data available
---